Submitter:	Incisive Surgical
Contact Person:	14405 21st Avenue North, Suite 130, Plymouth, MN 55447-2000 James Peterson, Vice President, Ph. (952) 591- 2543 ext 14
Date Prepared:	James Peterson, Vice President, Ph: (952) 591- 2543 ext 14 January 21, 2009
Trade Name:	INSORB™ Absorbable Staple
Classification	
Product Code:	Class II, 21 CFR 8787.4750, Staple, Implantable GDW
Predicate Device	GDW
and 510(k) No.	INSORB™ Absorbable Staple K061784
Device Description:	INSORB™ Absorbable Staples are 5 mm in length, 0.8 mm thick, 3.5 mm wide overall, and have cleat tips that are 0.8 mm apart. They are used in conjunction with a manual surgical stapler from Incisive (Note: Incisive's manual surgical stapler is a Class I exempt device pursuant to 21 CFR 878.4800 and is not the subject of this submission).
Intended Use:	Synthetic absorbable INSORB™ staples are intended for use in abdominal, thoracic, gynecologic, orthopedic, plastic and reconstructive surgery for the subcuticular closure of skin where an absorbable tissue fastener is desired for temporary tissue approximation.
Statement of Technological Comparison	 The subject device and the predicate device are identical except for an optimization in the staple shape that allows the following specification changes: Minimum "peak load" pull strength specification for the staple in its "dry" as packaged state is increased 25% to 1.500-lbs. Minimum "peak load" pull strength specification for the staple following exposure to 37°C buffered saline for 1-day is increased 25% to 0.750-lbs Minimum "peak load" pull strength specification for the staple following exposure to 37°C buffered saline for 7-days is increased 25% to 0.375-lbs.
Conclusion:	The modified INSORB Absorbable Staple described in this submission is substantially equivalent to the predicate device.



FEB - 6 2009

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Incisive Surgical, Inc.
% Mr. James Peterson
Vice President
14405 21st Avenue North, Suite 130
Plymouth, Minnesota 55447-2000

Re: K090159

Trade/Device Name: INSORB[™] Absorbable Staples

Regulation Number: 21 CFR 878.4750 Regulation Name: Implantable staple

Regulatory Class: II Product Code: GDW Dated: January 21, 2009 Received: January 22, 2009

Dear Mr. Peterson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. James Peterson

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark of Milkers

Mark N. Melkerson

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known)

K090159

Device Name

INSORB™ Absorbable Staples

Indications for Use Synthetic absorbable INSORB™ staples are intended for use in abdominal, thoracic, gynecologic, orthopedic, plastic and reconstructive surgery for the subcuticular closure of skin where an absorbable tissue fastener is desired for temporary tissue approximation.

Stapler is designed to aid in the prevention of accidental needle stick injuries.

Prescription Use <u>Yes</u> (Per 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

<u>No</u>

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

510(k) Number 16090155